Elucidating the roles and mechanisms of activation of NLRP3 inflammasomes and developing therapeutic interventions for severe steroid-resistant asthma

阐明 NLRP3 炎症小体激活的作用和机制并开发治疗严重类固醇抵抗性哮喘的治疗干预措施

• 批准号: nhmrc : 1120252
• 负责人: Prof Matthew Cooper
• 金额: $ 65.65万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/elucidating-roles-mechanisms-resistant-asthma/946474
• 关键词: Elucidating; roles; mechanisms; activation; NLRP3

Severe asthma is a major clinical issue. There are no effective treatments because we don’t understand how it occurs. We have identified a factor called an “inflammasome” that we think causes severe asthma. We have produced a new inhibitor of this factor, and shown experimentally that it may suppress important symptoms of severe asthma. We now aim to work out precisely how this inflammasome causes severe asthma and progress our new inhibitor towards therapeutic development.

严重哮喘是一个主要的临床问题。没有有效的治疗方法，因为我们不知道它是如何发生的。我们已经确定了一种被称为“炎性体”的因子，我们认为它会导致严重的哮喘。我们已经生产了一种新的这种因子的抑制剂，并通过实验证明它可以抑制严重哮喘的重要症状。我们现在的目标是精确地找出这种炎性小体是如何引起严重哮喘的，并将我们的新抑制剂推向治疗发展。